Despite their potential, RNA-based therapies are faced with major challenges: The instability of RNA and its rapid degradation in the body, combined with the necessity of ultra-cold storage or ...

Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

The Nasdaq is one of the top three most-followed stock market indices in the United States, comprising over 2,500 stocks.

Labomatic Instruments and Knauer recently announced a new strategic cooperative relationship to offer their instrument portfolios to each other’s customer bases.

BMO Capital Markets reaffirmed their Outperform rating on Beam Therapeutics Inc (NASDAQ:BEAM), with a steady price target of $57.00. Currently trading at $26.57, the stock appears undervalued ...